DTaP-IPV/Hib vaccine (Pentacel)

Area of Science:

• Pediatric Vaccinology
• Immunology
• Infectious Disease Prevention

Background:

• The DTaP-IPV/Hib vaccine is the first US-approved DTaP-based combination vaccine including poliovirus and Haemophilus influenzae type b (Hib) antigens.
• This vaccine has been used in Canada for over a decade, demonstrating its established use and efficacy.

Purpose of the Study:

• To evaluate the immunogenicity and tolerability of the DTaP-IPV/Hib combination vaccine in infants.
• To compare the immune responses induced by the combination vaccine with those of separately administered vaccines.

Main Methods:

• Clinical trials involving infant administration of a four-dose DTaP-IPV/Hib vaccine series.
• Immunogenicity assessments measuring seroprotection against diphtheria, tetanus, poliovirus, Hib, and pertussis components.
• Serology bridging studies to compare responses with existing DTaP vaccines.
• Evaluation of coadministration with other routine infant vaccines.

Main Results:

• High immunogenicity and seroprotection rates were observed for all vaccine antigens, including Hib.
• Immune responses after doses 3 and 4 were generally noninferior to separate vaccines, with minor exceptions.
• Seroconversion rates for pertussis components were noninferior to separate vaccines.
• No clinically significant impact on immunogenicity when coadministered with pneumococcal, MMR, and varicella vaccines.
• Tolerability profile was similar to separately administered vaccines.

Conclusions:

• The DTaP-IPV/Hib combination vaccine is highly immunogenic and well-tolerated in infants.
• It provides robust protection comparable to separate vaccines, simplifying immunization schedules.
• This vaccine represents a significant advancement in pediatric infectious disease prevention.